Clinical data
Routes of
ATC code none
Legal status
Legal status
  • Clinical phase II
CAS Number 152811-62-6 YesY
PubChem (CID) 177336
ChemSpider 154413 N
Chemical and physical data
Formula C22H31N3O2
Molar mass 369.50 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Piboserod is a selective 5-HT4 receptor antagonist which was marketed and manufactured by GlaxoSmithKline (GSK) under the trade name Serlipet for the management of atrial fibrillation and irritable bowel syndrome. In 2007 the Norwegian company Bio-Medisinsk Innovasjon AS (BMI)[1] completed a clinical phase II study to investigate the effect of piboserod in patients with chronic heart failure.

Mechanism of action

In 2002 a research group at the University of Oslo discovered that muscles from the ventricle of failing hearts have increased responsiveness to serotonin.[2] They later demonstrated that the effect was due to an expression of functional 5-HT4 receptors in the failing muscle. On the basis of these findings, and in analogy with the success of betablockers in heart failure, the group made the hypothesis that 5-HT4 receptor antagonists could be useful to treat heart failure. Their hypothesis was tested in animal models of heart failure with positive results.[3]


  1. Company web-page
  2. Bratteli, T.; et al. (2004). "Functional serotonin 5-HT4 receptors in porcine and human ventricular myocardium with increased 5-HT4 mRNA in heart failure. Naunyn-Schmiedeberg's". Arch. Pharmacol. 370: 157–166. doi:10.1007/s00210-004-0963-0.
  3. Birkeland, JA.; et al. (Jan 2007). "Effects of treatment with a 5-HT4 receptor antagonist in heart failure". Br J Pharmacol. 150 (2): 143–52. doi:10.1038/sj.bjp.0706966.
This article is issued from Wikipedia - version of the 5/31/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.